Reparixin ( DrugBank: Reparixin )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
298	Hereditary pancreatitis	1
299	Cystic fibrosis	1

298. Hereditary pancreatitis

---

Clinical trials : 95 /  Drugs : 148 - (DrugBank : 51) / Drug target genes : 53 - Drug target pathways : 142

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01967888 (ClinicalTrials.gov)	February 2014	18/10/2013	Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation	A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation	Pancreatectomy for Chronic Pancreatitis	Drug: Reparixin;Drug: Placebo	Dompé Farmaceutici S.p.A	NULL	Completed	18 Years	N/A	All	104	Phase 2/Phase 3	United States;Canada

299. Cystic fibrosis

---

Clinical trials : 1,695 /  Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2009-013340-36-IT (EUCTR)	25/01/2010	31/12/2009	PREVENTION OF REPERFUSION INJURY IN HUMAN LUNG TRANSPLANTATION FOR CYSTIC FIBROSIS BY TARGETING IL-8 ACTIVITY - ND	PREVENTION OF REPERFUSION INJURY IN HUMAN LUNG TRANSPLANTATION FOR CYSTIC FIBROSIS BY TARGETING IL-8 ACTIVITY - ND	cystic fibrosis MedDRA version: 12.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis	Product Name: reparixin INN or Proposed INN: Reparixin	IST. DI RICERCHE FARMACOLOG. M. NEGRI	NULL	Not Recruiting			Female: yes Male: yes			Italy